P
SUPN icon

Pitcairn’s Supernus Pharmaceuticals SUPN Stock Holding History

Pitcairn’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,737
Closed -$244K – 710
2025
Q2 		$244K Sell
7,737
-1,396
-15% -$44.7K 0.02% 621
2025
Q1 		$299K Buy
9,133
+166
+2% +$5.88K 0.02% 577
2024
Q4 		$324K Buy
8,967
+149
+2% +$5.25K 0.02% 561
2024
Q3 		$275K Sell
8,818
-1,033
-10% -$32.2K 0.02% 613
2024
Q2 		$264K Buy
9,851
+668
+7% +$19.4K 0.02% 620
2024
Q1 		$313K Buy
9,183
+109
+1% +$3.25K 0.02% 567
2023
Q4 		$263K Sell
9,074
-75
-0.8% -$1.99K 0.02% 579
2023
Q3 		$252K Buy
9,149
+521
+6% +$15.9K 0.02% 551
2023
Q2 		$259K Sell
8,628
-64
-0.7% -$2.24K 0.02% 553
2023
Q1 		$315K Sell
8,692
-176
-2% -$6.77K 0.03% 475
2022
Q4 		$316K Sell
8,868
-333
-4% -$11.6K 0.03% 449
2022
Q3 		$311K Buy
9,201
+150
+2% +$4.88K 0.03% 416
2022
Q2 		$262K Buy
9,051
+52
+0.6% +$1.49K 0.03% 479
2022
Q1 		$291K Buy
8,999
+523
+6% +$16K 0.03% 508
2021
Q4 		$247K Buy
+8,476
New +$257K 0.02% 573
2018
Q3 		– Sell
-8,138
Closed -$487K – 545
2018
Q2 		$487K Sell
8,138
-724
-8% -$37.5K 0.05% 261
2018
Q1 		$406K Buy
8,862
+392
+5% +$16.4K 0.04% 287
2017
Q4 		$337K Buy
8,470
+273
+3% +$10.8K 0.03% 356
2017
Q3 		$328K Sell
8,197
-40
-0.5% -$1.73K 0.04% 340
2017
Q2 		$355K Sell
8,237
-731
-8% -$26K 0.04% 303
2017
Q1 		$281K Sell
8,968
-337
-4% -$9.03K 0.03% 386
2016
Q4 		$235K Sell
9,305
-2,219
-19% -$49.6K 0.03% 437
2016
Q3 		$285K Sell
11,524
-403
-3% -$9.12K 0.04% 384
2016
Q2 		$243K Sell
11,927
-424
-3% -$7.52K 0.03% 383
2016
Q1 		$189K Buy
+12,351
New +$161K 0.02% 449

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pitcairn's SUPN Position: Q3 2025 in Review

Pitcairn sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 7,737 shares — an estimated $244K sold.

Pitcairn first reported a position in SUPN in Q1 2016 and held it in 25 quarters. The position peaked at $487K in Q2 2018. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Pitcairn reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Pitcairn sold 7,737 Supernus Pharmaceuticals shares in Q3 2025, an estimated $244K.
  • Pitcairn first reported a position in Supernus Pharmaceuticals in Q1 2016 and held it in 25 quarters.
  • Pitcairn's Supernus Pharmaceuticals position peaked at $487K in Q2 2018.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Pitcairn's 13F filing for Q3 2025, filed 12 Nov 2025.